Cartesian Therapeutics Raises $150M Credit Facility, Extends Runway into 2028
RNAC•Cartesian Therapeutics secured up to $150 million non-dilutive financing from K2 HealthVentures, including a $50 million tranche, extending its cash runway into 2028 and supporting pre-launch activities. Topline data from the Phase 3 AURORA trial in myasthenia gravis is expected in Q1 2027, with BLA filing planned mid-2027.
1. Financing Agreement Details
Cartesian entered a credit facility with K2 HealthVentures for up to $150 million, with an initial $50 million tranche funded at signing. Two additional $25 million tranches are available upon achieving clinical and financing milestones in 2027 and 2028, plus an optional $50 million draw at the company’s discretion.
2. Cash Runway and Pre-Launch Investments
Proceeds from the financing extend Cartesian’s cash runway into 2028 and accelerate pre-commercial launch activities for Descartes-08 in myasthenia gravis and myositis. The funding supports manufacturing scale-up, market access planning and broader operational investments ahead of potential approval.
3. Upcoming Clinical Readouts and Regulatory Plans
Topline data from the Phase 3 AURORA trial in MG is expected in Q1 2027, with a BLA filing planned for mid-2027. Data from the Phase 2 TRITON trial in myositis and the Phase 1/2 HELIOS pediatric trial in juvenile dermatomyositis are both anticipated in the first half of 2027.
